E-Vaccines

E-Vaccines is a Brazilian biotechnology company specializing in the development of recombinant protein vaccines for infectious diseases. Spun off from the Federal University of Minas Gerais (UFMG), the company utilizes its proprietary SpiN platform to create immunogens that elicit strong T-cell responses. Its lead candidate, SpiN-TEC, is a next-generation COVID-19 vaccine currently in Phase 1/2 clinical trials, designed to provide broader protection by targeting multiple viral proteins. E-Vaccines also maintains a pipeline of candidates for neglected tropical diseases, including human leishmaniasis and Chagas disease. The company has successfully commercialized veterinary vaccines and continues to collaborate with major Brazilian research institutions like Fiocruz.